Quidel Corporation (QDEL) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units.

Total Revenue Chart for Quidel Corporation

Quidel Corporation (QDEL) revenue for FY2025 was USD 2.7B, a -1.9% change from FY2024. Quidel Corporation's revenue grew from USD 9.5M in 1985 to USD 2.7B in 2025 (28638.9% over 40 years). Earnings per share grew from USD 0.03 in 2001 to USD 9.56 in 2022 (32715.2%). Revenue compound annual growth rate: 5-year CAGR of 10.4%, 10-year CAGR of 30.1%, 20-year CAGR of 18.5%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$941.54M
Implied Share Price
$13.73
Enterprise Value
$3.70B
Revenue (TTM)
$2.67B
EBITDA
$484.60M
Profit Margin
-39.20%
Trailing P/E
—
Forward P/E
9.59
Price/Book (MRQ)
0.42
Price/Sales (TTM)
0.35
EV/EBITDA
22.78
EV/Revenue
1.38
Dividend Yield
—
Book Value
$25.99
Free Cash Flow (FY2025)
-$83.00M
Free Cash Flow Yield
-8.82%

Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.